HULL HANS (Chief Business Officer) sold 6.0% of their position (8.75K shares) of PLIANT THERAPEUTICS, INC. on the open market
Open‑market sale worth $167.1K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/21/2022ACC: 0001140361-22-046567
Officer· Chief Business Officer
Since Jun 2020
+8.83K
Net shares
Net buyer
$167.1K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
17.58K acquired · 8.75K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+17.58K
Price / share
—
Trade value
—
% of position
13.6%
12/19/2022
129.36K→146.94K
Common Stock
Direct
Shares
−8.75K
Price / share
$19.10
Trade value
$167.11K
% of position
6.0%
12/20/2022
146.94K→138.19K
Total
Net shares
+8.83K
Net value
-$167.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/19/2022 | A · Award | +17.58K | — | — | 13.6% | 129.36K | 146.94K |
| Common Stock Direct | 12/20/2022 | S · Sale | −8.75K | $19.10 | $167.11K | 6.0% | 146.94K | 138.19K |
| Total | +8.83K | -$167.11K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned3.82K
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned13.98K
Total
31.79K indirect31.79K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 3.82K | Indirect |
| Common Stock | 13.98K | Indirect |
| Common Stock | 13.98K | Indirect |
| Total | 31.79K | 31.79K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported